Opinion
Video
Multiple Myeloma Challenges and Treatment Evolution
Gabriel Hinojosa, PharmD, BCOP, explores unmet needs and social determinants in multiple myeloma care, envisioning treatment advancements amid evolving complexities and patient disparities.
This is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP.
Hinojosa highlighted the prominent unmet need in multiple myeloma management: the absence of a cure and eventual exhaustion of treatment options. Despite recent additions to the treatment arsenal, achieving a cure remains elusive. The treatment landscape is evolving with the identification of new targets such as BCMA and GPRC5D, offering promising response rates. Bispecifics and chimeric antigen receptor T-cell agents have revolutionized patient treatment, with more in the pipeline, requiring continuous exploration of optimal sequencing and toxicity management. Social determinants of health significantly impact outcomes, especially for patients with lower incomes and limited resources, leading to challenges in medication adherence, treatment schedules, and financial toxicity. Addressing these social determinants is a crucial unmet need to enhance overall care for patients with multiple myeloma.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
